Literature DB >> 16226251

Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats.

Akira Ishihata1, Tomoko Ogaki, Tomomi Aita, Yumi Katano.   

Abstract

Endothelial function is modulated by aging. The objective of this study was to elucidate whether aging influences urotensin II-induced coronary vasodilatation, and whether aging influences the production of endothelial factors in response to urotensin II. We examined the effects of urotensin II on coronary flow in Langendorff-perfused rat hearts. The production of nitric oxide (NO), prostacyclin and prostaglandin (PG)E2 were determined in the coronary effluent of both young and aged rats. Urotensin II increased coronary flow in Langendorff-perfused hearts in both young and aged rats and vasodilation did not differ between young and aged rats. Pretreatment with a NO synthase inhibitor, NG-nitro-L-arginine (L-NNA), significantly inhibited urotensin II-induced vasodilatation in young rats, but not in aged rats. In addition, urotensin II increased the production of NO only in young rats. On the other hand, the cyclooxygenase inhibitor diclofenac significantly attenuated the urotensin II-induced coronary vasodilatation in both young and aged rats. Urotensin II markedly increased the release of the vasodilating prostacyclin and PGE2 into the coronary effluent. Production of these prostanoids was maintained even in the aged coronary arteries. These results indicate that the production of NO in the endothelium of coronary arteries is impaired in aged rats, and that prostacyclin and PGE2 may play an important role in regulating urotensin II-induced coronary vasodilatation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226251     DOI: 10.1016/j.ejphar.2005.09.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

2.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

3.  Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Authors:  Hao Qian; Na Luo; Yuling Chi
Journal:  J Aging Res       Date:  2012-02-13

4.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

5.  Advancing Age Decreases Pressure-Sensitive Modulation of Calcium Signaling in the Endothelium of Intact and Pressurized Arteries.

Authors:  Calum Wilson; Christopher D Saunter; John M Girkin; John G McCarron
Journal:  J Vasc Res       Date:  2017-01-19       Impact factor: 1.934

Review 6.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008

7.  A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.

Authors:  Roberta d'Emmanuele di Villa Bianca; Emma Mitidieri; Erminia Donnarumma; Ferdinando Fusco; Nicola Longo; Giuseppe De Rosa; Ettore Novellino; Paolo Grieco; Vincenzo Mirone; Giuseppe Cirino; Raffaella Sorrentino
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.